MRD as a Surrogate Endpoint for Efficacy Evaluation of New Drugs in Very High Risk ALL: Lessons from Ph ALL FDA Meeting; April 18th, 2012 Stephen P. Hunger, M.D. Chair, COG ALL Committee - Piperazines - Document - PDFSEARCH.IO

First Page		Document Content
Minimal residual disease Imatinib Chemotherapy Medicine Piperazines Philadelphia chromosome		MRD as a Surrogate Endpoint for Efficacy Evaluation of New Drugs in Very High Risk ALL: Lessons from Ph+ ALL FDA Meeting; April 18th, 2012 Stephen P. Hunger, M.D. Chair, COG ALL Committee Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 193,54 KB Share Document on Facebook